Subscribe

Beyond Martin Shkreli, pharma price hikes are common

Pharmaceutical hikes shocked patients for decades before hedge fund manager Martin Shkreli jacked up the price of a common prescription drug last week. Will this round of public outrage bring real change?

  • close
    Mishi Mohammed, a phlebotomist, holds a blood sample from a woman to test for HIV at the Mater Hospital in Kenya's capital Nairobi, September 10, 2015. Most of the 3,000 patients at Mater Hospital's Comprehensive Care Clinic, dedicated to HIV/AIDS treatment, come from nearby shanty towns.
    Thomas Mukoya/Reuters/File
    View Caption
  • About video ads
    View Caption
of

Martin Shkreli, a former hedge fund manager and current CEO of Turing Pharmaceuticals, sparked public and official outrage recently after raising the price of Daraprim, a drug commonly used by AIDS and cancer patients, 5,000 percent overnight. The Infectious Diseases Society of America detailed the shift from $13.50 to $750 per pill in a letter addressed to Turing, urging the company to reverse the decision. 

Daraprim is not the first drug Mr. Shkreli has attempted to increase in price. In September of 2014, Retrophin, a pharmaceutical company run by then-CEO Shkreli, came under fire for increasing the price of Thiola, another prescription drug. The price increase was from $1.50 to $30.00 per pill.

Both times Shkreli has led companies in a major price hike of prescription drugs, public outrage has ensued. But he is not the only one to utilize the tactic. In 2011, the price of a medical drug was raised 7,500 percent overnight, and Shkreli had nothing to do with it.

In 2011, KV Pharmaceuticals won government approval to be the exclusive supplier of makena, a drug that aims to prevent preterm labor. The price for makena immediately increased from $10 to $20 per injection to $1,500 per injection.

Dr. Roger Snow, deputy medical director for Massachusetts’ Medicaid program, told TwinCities.com, "That's a huge increase for something that can't be costing them that much to make. For crying out loud, this is about making money.”

Earlier this month, the price of cycloserine went from $15 per pill to $360. Cycloserine has been produced since the 1960s affordably. The rights to produce the drug were given to Rodelis Therapeutics a month before the price increase.

"Everyone in the TB community in North America has been going crazy over the last week or so when they realized the price had gone up by over 2,000 per cent," said Amir Attaran, a professor of law and medicine at the University of Ottawa, to CBC News.

In 2014, The Times of India reported Sofosbuvir, a Hepatitis C medicine, was being sold in India for $300 per bottle, or 1 percent of the price of the same drug in the US. Most baffling, Gilead, the pharmaceutical company selling the drug in India, is the same company selling the drug in the US. Gilead also offered voluntary licensing deals to seven other small pharmaceutical companies in India.

Pharmaceutical companies are quick to offer rationales for price hikes and differentiations between countries.

Shkreli said in an interview with CNBC News by rising prices Turing Pharmaceuticals is “dramatically increasing the access to daraprim, lowering co-pays, giving more drugs away for free.”

Uwe Reinhardt, a health-care economist from Princeton University, disagreed with Shkreli, saying to the Washington Post, "He bought this patent and he's milking it for all it's worth. In a way, I thank him…. Sometimes you need some sentinel effect that wakes people up."

In at least two cases, public attention has caused a partial reverse in pricing decisions. Rodelis Therapeutics, which raised the price of cycloserine by 2000 percent, gave the rights to the drug back to the nonprofit Chao Center, which produced the drug since 2007, according to International Business Times. Turing Pharmaceuticals has also announced an undisclosed price decrease for daraprim, according to NBC News.

Democratic presidential candidate Hillary Clinton unveiled a plan to lower prescription drug costs Tuesday. Fellow presidential candidate and US Sen. Bernie Sanders is currently sponsoring legislation to allow Medicaid to negotiate for lower drug prices. 

About these ads
Sponsored Content by LockerDome
 
 
Make a Difference
Inspired? Here are some ways to make a difference on this issue.
FREE Newsletters
Get the Monitor stories you care about delivered to your inbox.
 

We want to hear, did we miss an angle we should have covered? Should we come back to this topic? Or just give us a rating for this story. We want to hear from you.

Loading...

Loading...

Loading...

Save for later

Save
Cancel

Saved ( of items)

This item has been saved to read later from any device.
Access saved items through your user name at the top of the page.

View Saved Items

OK

Failed to save

You reached the limit of 20 saved items.
Please visit following link to manage you saved items.

View Saved Items

OK

Failed to save

You have already saved this item.

View Saved Items

OK